Literature DB >> 7489753

Natural antibodies against the immunoglobulin F(ab')2 fragment cause elimination of antigens recognized by the F(ab')2 from the circulation.

S Yano1, S Kaku, K Suzuki, C Terazaki, T Sakayori, T Kawasaki, K Kawamura, Y Sugita, K Hoshino, Y Masuho.   

Abstract

A humanized monoclonal IgG1 antibody, designated hC4G1, recognizes the fibrinogen receptor glycoprotein (GP)IIb/IIIa on platelets and inhibits platelet aggregation. When the F(ab')2 fragment of hC4G1 (F(ab')2 hC4G1) was administered to cynomolgus monkeys, all the monkeys showed inhibition of platelet aggregation ex vivo. Unexpectedly, a significant decrease in platelet count was observed in 5 of 18 monkeys. Antibodies against F(ab')2 hC4G1 were detected in the plasma of these monkeys by ELISA. Antibody activity in the plasma of these monkeys was significantly correlated with the intensity of platelet decrease (r = 0.84). The natural monkey antibodies to F(ab')2 hC4G1 were directed against the C-terminal region of F(ab')2 fragment common to all human and humanized IgG antibodies. Natural homo-reactive antibodies were also detected in human plasma from 15 of 40 healthy volunteers. Specificity was closely similar to that of the monkey antibodies. Affinity-purified human homoreactive antibodies enhanced phagocytosis of platelets treated with the F(ab')2 hC4G1. Monkey plasma with high homo-reactive antibody activity was confirmed to decrease platelet count when administered together with F(ab')2 hC4G1 to a monkey with low antibody activity. These results suggest that F(ab')2 of humanized and human antibodies causes elimination of the corresponding antigens from the circulation by homo-reactive antibodies.

Entities:  

Mesh:

Substances:

Year:  1995        PMID: 7489753     DOI: 10.1002/eji.1830251121

Source DB:  PubMed          Journal:  Eur J Immunol        ISSN: 0014-2980            Impact factor:   5.532


  10 in total

1.  Alternative complement pathway induction by ANCA.

Authors:  Hans U Lutz
Journal:  Am J Pathol       Date:  2008-08-07       Impact factor: 4.307

2.  A monoclonal antibody against hinge-cleaved IgG restores effector function to proteolytically-inactivated IgGs in vitro and in vivo.

Authors:  Randall J Brezski; Michelle Kinder; Katharine D Grugan; Keri L Soring; Jill Carton; Allison R Greenplate; Theodore Petley; Dorie Capaldi; Kerry Brosnan; Eva Emmell; Sharon Watson; Robert E Jordan
Journal:  MAbs       Date:  2014-10-30       Impact factor: 5.857

3.  Autoantibodies to variable heavy (VH) chain Ig sequences in humans impact the safety and clinical pharmacology of a VH domain antibody antagonist of TNF-α receptor 1.

Authors:  M C Holland; J U Wurthner; P J Morley; M A Birchler; J Lambert; M Albayaty; A P Serone; R Wilson; Y Chen; R M Forrest; J C Cordy; D A Lipson; A I Bayliffe
Journal:  J Clin Immunol       Date:  2013-07-06       Impact factor: 8.317

4.  The in vitro resistance of IgG2 to proteolytic attack concurs with a comparative paucity of autoantibodies against peptide analogs of the IgG2 hinge.

Authors:  Randall J Brezski; Allison Oberholtzer; Brandy Strake; Robert E Jordan
Journal:  MAbs       Date:  2011-11-01       Impact factor: 5.857

Review 5.  Cleavage of IgGs by proteases associated with invasive diseases: an evasion tactic against host immunity?

Authors:  Randall J Brezski; Robert E Jordan
Journal:  MAbs       Date:  2010-05-23       Impact factor: 5.857

6.  Molecular characterization of human anti-hinge antibodies derived from single-cell cloning of normal human B cells.

Authors:  Tao Huang; Mary Mathieu; Sophia Lee; Xinhua Wang; Yee Seir Kee; Jack J Bevers; Claudio Ciferri; Alberto Estavez; Manda Wong; Nancy Y Chiang; Gerald Nakamura; Randall J Brezski
Journal:  J Biol Chem       Date:  2017-11-30       Impact factor: 5.157

7.  Preexisting Antibodies to an F(ab')2 Antibody Therapeutic and Novel Method for Immunogenicity Assessment.

Authors:  Jane Ruppel; Ann Brady; Rebecca Elliott; Cecilia Leddy; Marco Palencia; Daniel Coleman; Jessica A Couch; Eric Wakshull
Journal:  J Immunol Res       Date:  2016-06-16       Impact factor: 4.818

8.  Pre-existing canine anti-IgG antibodies: implications for immunotherapy, immunogenicity testing and immunoassay analysis.

Authors:  Daniel Bergman; Camilla Bäckström; Helene Hansson-Hamlin; Anders Larsson; Bodil Ström Holst
Journal:  Sci Rep       Date:  2020-07-29       Impact factor: 4.379

Review 9.  Proteinase-nicked IgGs: an unanticipated target for tumor immunotherapy.

Authors:  Robert E Jordan; Xuejun Fan; Georgina Salazar; Ningyan Zhang; Zhiqiang An
Journal:  Oncoimmunology       Date:  2018-07-23       Impact factor: 8.110

Review 10.  How immune complexes from certain IgG NAbs and any F(ab')₂ can mediate excessive complement activation.

Authors:  Hans U Lutz
Journal:  Adv Exp Med Biol       Date:  2012       Impact factor: 2.622

  10 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.